Novel Targets for the Treatment of Melanoma

被引:18
作者
Ambrosi, Lara [1 ]
Khan, Shaheer [2 ]
Carvajal, Richard D. [2 ]
Yang, Jessica [2 ]
机构
[1] Stony Brook SOM, 101 Nicholls Rd, Stony Brook, NY 11794 USA
[2] Columbia Univ, Med Ctr, Div Hematol Oncol, 177 Ft Washington Ave,MHB 6GN-435, New York, NY 10032 USA
关键词
Melanoma; Immunotherapy; Checkpoint inhibitors; CTLA-4; PD-1; PD-L1; Targeted therapy; MEK inhibitor; BRAF inhibitor; Oncolytic therapy; TUMOR-INFILTRATING LYMPHOCYTES; LONG-TERM SURVIVAL; ADOPTIVE CELL THERAPY; OPEN-LABEL PHASE-3; CD8(+) T-CELLS; METASTATIC MELANOMA; IMMUNE CHECKPOINT; ANTITUMOR-ACTIVITY; KINASE INHIBITOR; BRAF INHIBITION;
D O I
10.1007/s11912-019-0849-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review In this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies. Recent Findings Over the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell-based therapies, intratumoral agents, and others are ongoing. While strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
引用
收藏
页数:16
相关论文
共 152 条
  • [81] Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
    Hutson, Thomas E.
    Lesovoy, Vladimir
    Al-Shukri, Salman
    Stus, Viktor P.
    Lipatov, Oleg N.
    Bair, Angel H.
    Rosbrook, Brad
    Chen, Connie
    Kim, Sinil
    Vogelzang, Nicholas J.
    [J]. LANCET ONCOLOGY, 2013, 14 (13) : 1287 - 1294
  • [82] CD40-activated B cells contribute to mesothelioma tumor regression
    Jackaman, Connie
    Cornwall, Scott
    Graham, Peter Thomas
    Nelson, Delia Jane
    [J]. IMMUNOLOGY AND CELL BIOLOGY, 2011, 89 (02) : 255 - 267
  • [83] The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses
    Johnston, Robert J.
    Yu, Xin
    Grogan, Jane L.
    [J]. ONCOIMMUNOLOGY, 2015, 4 (09): : 1 - 2
  • [84] Expression of Costimulatory Ligand CD70 on Steady-State Dendritic Cells Breaks CD8+ T Cell Tolerance and Permits Effective Immunity
    Keller, Anna M.
    Schildknecht, Anita
    Xiao, Yanling
    van den Broek, Maries
    Borst, Jannie
    [J]. IMMUNITY, 2008, 29 (06) : 934 - 946
  • [85] Rationale for anti-GITR cancer immunotherapy
    Knee, Deborah A.
    Hewes, Becker
    Brogdon, Jennifer L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 67 : 1 - 10
  • [86] Development of TLR9 agonists for cancer therapy
    Krieg, Arthur M.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (05) : 1184 - 1194
  • [87] OX40 controls functionally different T cell subsets and their resistance to depletion therapy
    Kroemer, Alexander
    Xiao, Xiang
    Vu, Minh Diem
    Gao, Wenda
    Minamimura, Keisuke
    Chen, Ming
    Maki, Takashi
    Li, Xian Chang
    [J]. JOURNAL OF IMMUNOLOGY, 2007, 179 (08) : 5584 - 5591
  • [88] Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells
    Kwon, SH
    Ahn, SH
    Kim, YK
    Bae, GU
    Yoon, JW
    Hong, S
    Lee, HY
    Lee, YW
    Lee, HW
    Han, JW
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (03) : 2073 - 2080
  • [89] T-cell activation marker expression on tumor-infiltrating lymphocytes as prognostic factor in cutaneous malignant melanoma
    Ladányi, A
    Somlai, B
    Gilde, K
    Fejös, Z
    Gaudi, I
    Tímár, J
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (02) : 521 - 530
  • [90] Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
    Larkin, James
    Ascierto, Paolo A.
    Dreno, Brigitte
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Sovak, Mika A.
    Chang, Ilsung
    Choong, Nicholas
    Hack, Stephen P.
    McArthur, Grant A.
    Ribas, Antoni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20) : 1867 - 1876